Ficlatuzumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from mouse) |
| Target | HGF |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6446H9954N1718O2026S46 |
| Molar mass | 145409.30 g·mol−1 |
| (what is this?) (verify) | |
Ficlatuzumab is a humanized monoclonal antibody designed for the treatment of cancers.
It is a humanized monoclonal antibody that binds to hepatocyte growth factor, thus inhibiting the c-MET receptor signaling cascade.
Ficlatuzumab was developed by AVEO Pharmaceuticals. In May 2012, AVEO released results of a Phase II clinical trial comparing gefitinib alone and in combination with ficlatuzamab in treatment-naive Asian patients with non-small cell lung cancer.